- Institution: Stanford Univ Med Ctr Lane Med Lib/Periodical Dept/Rm L109
- Sign In as Member / Individual
Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges
Table 1.
Clinical Cardiovascular Phenotypes of COX-Isozyme Inhibition
| COX inhibitor | Platelet TXA2 | Whole Body PGI2 | Cardiovascular phenotype |
|---|---|---|---|
| Aspirin (50 100 mg) | Decreased by >97% | No significant changes | Cardioprotection |
| Aspirin (650 1,300 mg) | Decreased by >97% | Decreased 60–80% | Cardioprotection(Effects relative to lower doses are uncertain) |
| Naproxen (500 mg bid) | Decreased by ~95% | Decreased 60–80% | None/cardioprotection? |
| Other NSAIDs (high doses) | Decreased by 50–90% | Decreased 60–80% | Increased risk of myocardial infarction |
| Coxibs (high doses) | No significant changes | Decreased 60–80% | Increased risk of myocardial infarction |
